What medical tests should a clinician run when a man reports decreased penile sensitivity?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
When a man reports decreased penile sensitivity, clinicians should pursue a targeted, stepwise workup combining (A) a focused history to identify reversible causes such as pressure/trauma, medications, systemic disease and sexual-function context, (B) point‑of‑care sensory testing (vibrotactile/biothesiometry or quantitative sensory testing), (C) neurophysiological studies when neuropathy is suspected, and (D) directed laboratory screens including glycemic and hormonal testing; pelvic‑floor or specialist referral is frequently appropriate [1] [2] [3] [4] [5].
1. Initial clinical evaluation: elicit reversible drivers first
A clinician’s first test is a meticulous history because many common, reversible causes — prolonged cycling or sitting, tight clothing, topical irritation, recent penile trauma, and new medications (notably SSRIs and other psychotropics) — are identified by history alone and can resolve with behavioral change or medication review [1] [2] [6]. Age, erectile or ejaculatory complaints, prior pelvic surgery (eg, radical prostatectomy), and comorbid illnesses such as diabetes or multiple sclerosis should be explicitly sought because they change test selection and urgency [7] [4] [3].
2. Office sensory testing: biothesiometry and vibrotactile thresholds
Objective, noninvasive office measures of penile sensory thresholds are widely used; biothesiometry (vibratory testing) and the Penile Sensitivity Ratio (PSR, which compares glans and finger inputs) have been validated to differentiate men who report diminished sensitivity and correlate with age and some comorbidities, making them practical first‑line quantitative tools [3] [8]. Quantitative somatosensory testing protocols that measure touch, temperature and pain thresholds at penile sites provide complementary data and have been used in research and clinical settings to map deficits across stimulus types (vibration, touch, heat) [9].
3. Neurophysiology when neuropathy or post‑surgical change is suspected
When history or office testing suggests neuropathy — for example after pelvic trauma or radical prostatectomy — electrophysiological studies are informative: sensory nerve conduction studies and sensorial EMG of the dorsal penile (dorsal nerve of the penis) or pudendal pathways can detect reduced conduction velocity or amplitude, and thermal threshold testing can document small‑fiber dysfunction; such studies have demonstrated postoperative declines in nerve conduction after prostate surgery and can aid prognosis and management [4] [10].
4. Laboratory testing: metabolic and hormonal screens
Clinically important, treatable systemic contributors should be screened: glycemic testing (fasting glucose and/or hemoglobin A1c) is indicated because diabetes associates with higher penile sensory thresholds and neuropathy risk [3] [7]; serum testosterone assessment is warranted when low libido, erectile problems or other hypogonadal signs exist because low testosterone can alter sexual perception and arousal [5] [11]; consideration of thyroid testing is reasonable in the presence of systemic symptoms because thyroid dysfunction is cited as a possible contributor to sexual dysfunction [12].
5. Medication review, pelvic‑floor and specialty referrals
A careful medication reconciliation is a diagnostic “test” in practice — SSRIs and other agents have documented overlap with decreased genital sensitivity — and stopping or switching offending drugs when safe may restore sensation [2]. If exam or testing suggests pelvic musculature dysfunction, directed pelvic‑floor physical therapy is a commonly recommended next step; urology or neurology referral for advanced electrophysiology, or sexual medicine referral for complex cases such as Peyronie’s disease or “lost penis syndrome,” should follow [2] [13].
6. Caveats, evolving treatments and evidence gaps
Emerging regenerative or device therapies (low‑intensity shockwave, platelet injections/P‑Shot, clinic‑advertised procedures) are promoted in some practice settings but evidence varies and many reports are promotional rather than large randomized trials; clinicians should weigh objective testing and established diagnoses before pursuing such options and discuss limited quality evidence with patients [12]. Across sources, age, tumor surgery, diabetes and psychosocial factors repeatedly appear as drivers of decreased sensitivity, and objective testing (biothesiometry, quantitative sensory testing, nerve conduction/EMG) plus focused labs deliver the tractable answers most of the time [3] [8] [4] [5].